In the view of Wells Fargo, Biogen's (NASDAQ: BIIB) Tecfidera could be eroding some of Novartis' (NYSE: NVS) Gilenya growth ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE